Journal article

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

Huong D Meeks, Honglin Song, Kyriaki Michailidou, Manjeet K Bolla, Joe Dennis, Qin Wang, Daniel Barrowdale, Debra Frost, Lesley McGuffog, Steve Ellis, Bingjian Feng, Saundra S Buys, John L Hopper, Melissa C Southey, Andrea Tesoriero, Paul A James, Fiona Bruinsma, Ian G Campbell, Annegien Broeks, Marjanka K Schmidt Show all

Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2016

Grants

Awarded by Australian NHMRC Project


Awarded by National Institutes of Health (NIH)


Awarded by NIH specialized program of research excellence in breast cancer


Awarded by Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) data management and analysis through Cancer Research-UK grant


Awarded by Cancer Research UK


Awarded by European Community's Seventh Framework Programme


Awarded by European Union COST programme


Awarded by Ovarian Cancer Research Fund


Awarded by US National Cancer Institute Genetic Associations and Mechanisms in Oncology (GAME-ON) Post-Genome Wide Association Study (GWAS) Initiative


Awarded by Wellcome Trust


Awarded by European Community's Seventh Framework Programme (COGS)


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative (GAME-ON initiative)


Awarded by Department of Defence


Funding Acknowledgements

This work was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research and the Ministere de l'Economie, de l'Innovation et des Exportations du Quebec through Genome Quebec.Amanda Spurdle is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship, and aspects of this research were funded by Australian NHMRC Project grant ID #1010719. This work was also supported in part by National Institutes of Health (NIH) grants CA128978 and CA116167, an NIH specialized program of research excellence in breast cancer to the Mayo Clinic (P50 CA116201), and the Breast Cancer Research Foundation. The The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) data management and analysis is funded through Cancer Research-UK grant C12292/A11174. Breast Cancer Association Consortium (BCAC) data management was funded by Cancer Research UK (C1287/A10118 and C1287/A12014) and by the European Community's Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175). BCAC meetings have been funded by the European Union COST programme (BM0606). Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute Genetic Associations and Mechanisms in Oncology (GAME-ON) Post-Genome Wide Association Study (GWAS) Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available at http://www.wtccc.org.uk/. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by the Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute.Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/ A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/ A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.